[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531099":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":24,"studyPopulation":17,"armGroups":25,"interventions":32,"overallOfficials":38,"centralContacts":42,"locations":51,"responsibleParty":68,"collaborators":17,"id":70,"slug":17,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":17,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":17,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":53,"whyStopped":17,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Second Affiliated Hospital of Guangzhou Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Number of Patients with Dose Limiting Toxicity","A dose limiting toxicity is defined as any toxicity that is considered to be primarily related to the vaccine, which is irreversible, or life threatening or hematologic or non-hematologic Grade 3-5.","Six months",[14],{"measure":15,"description":16,"timeFrame":12},"Percent of Patients with best response as either complete remission or partial remission.","Response rates will be estimated as the percent of patients whose best response is either complete remission or partial remission by combining the data from the patients. To compare with historical data, a 95% confidence interval will be calculated for the response rate.",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"NA","SINGLE_GROUP","TREATMENT",{"masking":23,"maskingDescription":17,"whoMasked":17},"NONE","1. Choose appropriate patients with advanced solid cancers, with written consent for this study;\n2. Perform biopsy to get fresh sample for DNA\u002FRNA-seqencings and bioinformatics analysis;\n3. Produce high quality mRNA vaccine and deliver the vaccine into selected patients via local injections, and follow up closely to collect related results as required;\n4. To enhance the killing capability, cotreatment the patients with PD1\u002FPDL1\u002FCTLA4 antibodies may be applied;\n5. Evaluate the clinical results as needed.",[26],{"label":27,"type":28,"description":29,"interventionNames":30},"Anti-cancer Neoantigen mRNA Vaccine","EXPERIMENTAL","Anti-cancer neoantigen mRNA vaccine will be produced to treat advanced solid tumors.",[31],"Biological: Neoantigen mRNA Vaccine",[33],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":17},"BIOLOGICAL","Neoantigen mRNA Vaccine","Deliver neoantigen mRNA vaccine into patients for anti-ancer therapy.",[27],[39],{"name":40,"affiliation":5,"role":41},"Zhenfeng Zhang, MD, PhD","PRINCIPAL_INVESTIGATOR",[43,47],{"name":40,"role":44,"phone":45,"phoneExt":17,"email":46},"CONTACT","0086-020-39195965","zhangzhf@gzhmu.edu.cn",{"name":48,"role":44,"phone":49,"phoneExt":17,"email":50},"Bingjia He, MD","+862039195965","464677938@qq.com",[52],{"facility":5,"status":53,"city":54,"state":55,"zip":17,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"RECRUITING","Guangzhou","Guangdong","China","CN",{"type":59,"coordinates":60},"Point",[61,62],113.25,23.11667,{"lat":62,"lon":61},[65],{"name":66,"role":44,"phone":67,"phoneExt":17,"email":46},"Zhang Zhenfeng, MD, PhD","+862039195966",{"type":69,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100531099",false,"NCT06195384","Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors","Anti-cancer Neoantigen mRNA Vaccine to Treat Advanced Solid Tumors: Phase I Clinical Trial","Inclusion Criteria:\n\n1\\. Patients with advanced cancer; 2. Life expectancy \\>12 weeks; 3. Adequate heart, lung, liver, kidney, and blood function; 4. Available high quality vaccine for human use; 5. Informed consent explained to, understood by and signed by patient\u002Fguardian. Patient\u002Fguardian given copy of informed consent.\n\n\\-\n\nExclusion Criteria:\n\n1. Had accepted gene therapy before;\n2. Severe virus infection such as HBV, HCV, HIV, et al;\n3. Known HIV positivity;\n4. Active infectious disease related to bacteria, virus,fungi,et al;\n5. Other severe diseases that the investigators consider not appropriate;\n6. Pregnant or lactating women;\n7. Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent\u002Fkg\u002Fday);\n8. Other conditions that the investigators consider not appropriate.","ALL","18 Years","75 Years",{"count":80,"type":81},30,"ESTIMATED","INTERVENTIONAL",[84],"PHASE1","The WES and RAN-seq will be performed to identify and verify neoantigens and appropriate mRNA sequences will be verified, manufactured and protected for vaccine production by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the mRNA vaccine for immunotherapy of human cancer patients. In this phase I study, the safety, tolerance, and preliminary efficacy of the mRNA vaccine immunotherapy on human cancers will firstly be evaluated.",[87],"Solid Tumor, Adult",[89,90,91],"mRNA Vaccine","Solid Tumor","Immunotherapy","2024-06-22",{"date":94,"type":95},"2024-06-26","ACTUAL",{"date":97,"type":95},"2024-05-08",{"date":99,"type":81},"2037-12-30",{"name":5,"class":6},1]